Specifications
Immunogen
Synthetic peptide conjugated to KLH derived from within residues 250 to the C-terminus of Human Proteasome 20S LMP7.
Applications
Application Notes
WB: Use at a concentration of 1 μg/ml. Detects a band of approximately 22 kDa (predicted molecular weight: 30 kDa).
Target
Alternative Names
PSMB8; proteasome (prosome, macropain) subunit, beta type, 8; JMP; ALDD; LMP7; NKJO; D6S216; PSMB5i; RING10; D6S216E; proteasome subunit beta type-8; macropain subunit C13; proteasome subunit Y2; protease component C13; proteasome component C13; proteasom
Product Background
Antigen Description
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency.
Pathway
APC/C-mediated degradation of cell cycle proteins; APC/C:Cdc20 mediated degradation of mitotic proteins; AUF1 (hnRNP D0) destabilizes mRNA; Activation of NF-kappaB in B cells
Citations
Publication ()
Have you cited DPABH-18235 in a publication?
Let us know and earn a reward for your research.
COA
Loading ......
